Mainz Biomed reports 1H EPS (48c) vs. ($1.00) last year

Reports 1H revenue $520,773 vs. $499,049 last year. “2024 has been a transitional year for Mainz Biomed (MYNZ). While navigating through a period of difficult markets, especially for small cap technology stocks, we are proud to have achieved many significant accomplishments to date,” commented Guido Baechler, CEO. “As the Board and management team evaluated our path forward, we believe that a narrower focus on key strategic initiatives gives us the best opportunity to unlock shareholder value in the remainder of 2024 and 2025.”